Mesoblast highlights Ryoncil launch success at US healthcare conferences

Mesoblast has reported that the commercial launch of Ryoncil (remestemcel-L-rknd), its FDA-approved mesenchymal stromal cell (MSC) product, was a focal point at recent global healthcare conferences in New York. According to the company, the product is the first FDA-approved MSC therapy, approved for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged […] The post Mesoblast highlights Ryoncil launch success at US healthcare conferences appeared first on Longevity.Technology.